1. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial.
- Author
-
Pace D, Snape M, Westcar S, Oluwalana C, Yu LM, Begg N, Wysocki J, Czajka H, Maechler G, Boutriau D, and Pollard AJ
- Subjects
- Antibodies, Bacterial biosynthesis, Antibodies, Bacterial blood, Antibodies, Viral biosynthesis, Female, Haemophilus Infections prevention & control, Haemophilus Vaccines adverse effects, Haemophilus influenzae type b immunology, Humans, Immunization Schedule, Infant, Male, Measles-Mumps-Rubella Vaccine adverse effects, Measles-Mumps-Rubella Vaccine immunology, Meningitis, Meningococcal prevention & control, Neisseria meningitidis, Serogroup C immunology, Poland, Tetanus Toxoid adverse effects, United Kingdom, Vaccines, Conjugate adverse effects, Vaccines, Conjugate immunology, Haemophilus Vaccines immunology, Immunization, Secondary adverse effects, Tetanus Toxoid immunology
- Abstract
Objective: To study the immunogenicity and reactogenicity of a combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine (Hib-MenC-TT) when administered as a booster dose in combination with a measles, mumps and rubella vaccine (MMR)., Design: A phase 3 open randomised controlled trial., Setting: One centre in Oxford, UK and nine centres in Poland., Subjects: 12-15-month-old healthy children., Interventions: In the primary stage of the study 500 healthy 6-12-week-old infants were randomised in a 3:1 ratio to receive Hib-MenC-TT+DTPa-IPV or MenC-CRM197 vaccine+DTPa-IPV-Hib. In the booster stage, 476 participants (190 in the UK and 286 in Poland) were vaccinated with Hib-MenC-TT and MMR., Main Outcome Measures: The proportion of children with protective serum antibody levels against MenC and Hib 6 weeks following a Hib-MenC-TT booster dose., Results: The co-primary objectives were met: the Hib-MenC-TT booster dose induced protective antibody titres in children vaccinated with Hib-MenC-TT+DTPa-IPV or MenC-CRM197+DTPa-IPV-Hib at 2, 3 and 4 months of age. 94.8% (lower limit of (LL) 95% CI 92.4) of participants had rSBA-MenC >or=1:128 and 100% (LL 95% CI 99.2) achieved anti-PRP concentrations >or=1.0 microg/ml. The percentage of toddlers with a post boost rSBA-MenC of 1:128 was significantly higher after priming with Hib-MenC-TT (97.7%) than after MenC-CRM197 (86%) (difference: 11.7%; 95% CI 6.2 to 19.4)., Conclusion: The waning antibody titres against Hib and MenC following primary immunisation can be boosted to protective levels by administering the Hib-MenC-TT vaccine at 12-15 months of age, supporting the recent introduction of this vaccine in the UK immunisation schedule to sustain protection of children against Hib and MenC disease., Trial Registration Number: NCT00258700. Study ID: 103974 (http://clinicaltrials.gov).
- Published
- 2008
- Full Text
- View/download PDF